EWTX (Edgewise Pharma) רווח נקי למניה (EPS TTM)

Edgewise Therapeutics (EWTX) is a biotech company in the trial stage, meaning market pricing will be determined following regulatory approval. The company's growth is fueled by patents, cash reserves, and the progress of its sevasemten and EDG-7500 drugs. Risks are mitigated through the therapy of rare muscle pathologies in adults and children. The current EPS YoY TTM growth rate visualizes profit dynamics, where the value 686.10 describes the current level.
EWTX (Edgewise Therapeutics Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator measures the earnings per share (EPS) trend over the last twelve months relative to the previous year, determining the efficiency of the business capitalization. By analyzing the current YoY ttm net income growth per share, an investor assesses the viability of Edgewise Therapeutics (EWTX) amidst fierce competition with pharma behemoths, where any deviations in this metric signal critical risks in drug development.